Joshua Brumm, chief executive of Dyne Therapeutics Inc, has been named chair of UK-based Amphista Therapeutics Ltd, which has technology for targeted protein degradation. Mr Brumm has been chief financial officer at US-based Kaleido Biosciences Inc and Versartis Inc, having managed initial public share offerings for both companies.
In addition to his executive roles in pharma, Mr Brumm was an investment banker at Citigroup and Morgan Stanley. He holds a BA in business administration from the University of Notre Dame, US.
Amphista Therapeutics announced the appointment on 20 September 2021.
Copyright 2021 Evernow Publishing Ltd.